Efforts to develop and implement evidence-based risk-stratified PSA screening are urgently needed to stop the rapid rise in distant stage prostate cancer and prevent the anticipated subsequent rise in prostate cancer mortality. This evidence concerns the gene KLK3 and prostate cancer.